ALKS:NGS-Alkermes plc (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | Nasdaq Global Select

Last Closing

USD 24.68

Change

+0.24 (+0.98)%

Market Cap

USD 8.87B

Volume

1.02M

Analyst Target

USD 19.73
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

+0.64 (+0.46%)

USD 13.68B
VTRS Viatris Inc

-0.59 (-5.00%)

USD 13.36B
ITCI Intracellular Th

-1.44 (-2.15%)

USD 7.72B
LNTH Lantheus Holdings Inc

+1.39 (+1.87%)

USD 4.49B
ALVO Alvotech

+0.06 (+0.44%)

USD 3.79B
HCM HUTCHMED DRC

+1.35 (+6.93%)

USD 3.23B
AVDL Avadel Pharmaceuticals PLC

-0.42 (-2.58%)

USD 2.99B
INDV Indivior PLC Ordinary Shares

+0.09 (+0.51%)

USD 2.93B
EVO Evotec SE ADR

+0.08 (+1.54%)

USD 2.51B
AMPH Amphastar P

+0.22 (+0.52%)

USD 2.06B

ETFs Containing ALKS

PSIL AdvisorShares Psychedelic.. 4.39 % 0.00 %

-0.01 (0%)

USD 6.89M
PSCH Invesco S&P SmallCap Heal.. 3.64 % 0.29 %

+0.52 (+0%)

USD 0.20B
TYNE 3.26 % 0.00 %

N/A

N/A
LABS 0.00 % 0.45 %

N/A

N/A
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

-0.12 (0%)

USD 0.10B
AFSM First Trust Active Factor.. 0.00 % 0.00 %

+0.21 (+0%)

USD 9.53M

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.03% 53% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.03% 53% F 35% F
Trailing 12 Months  
Capital Gain -13.56% 57% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.56% 57% F 38% F
Trailing 5 Years  
Capital Gain -19.13% 73% C 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.13% 73% C 38% F
Average Annual (5 Year Horizon)  
Capital Gain 11.53% 70% C- 71% C-
Dividend Return 11.53% 70% C- 69% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.89% 87% B+ 66% D+
Risk Adjusted Return 42.86% 87% B+ 75% C
Market Capitalization 8.87B 96% N/A 88% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 8.07 67% 76%
Price/Book Ratio 3.39 32% 31%
Price / Cash Flow Ratio 10.40 19% 25%
Price/Free Cash Flow Ratio 7.08 26% 32%
Management Effectiveness  
Return on Equity 46.22% 96% 97%
Return on Invested Capital 36.16% 95% 94%
Return on Assets 12.81% 94% 97%
Debt to Equity Ratio 23.92% 53% 56%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector